Polskie Archiwum Medycyny Wewnętrznej
-
Myxedema coma and thyroid storm are among the most common endocrine emergencies presenting to general hospitals. Myxedema coma represents the most extreme, life‑threatening expression of severe hypothyroidism, with patients showing deteriorating mental status, hypothermia, and multiple organ system abnormalities. It typically appears in patients with preexisting hypothyroidism via a common pathway of respiratory decompensation with carbon dioxide narcosis leading to coma. ⋯ The diagnosis cannot be established based on laboratory tests alone, but several scoring systems are available. The usual clinical signs and symptoms of hyperthyroidism are present along with more exaggerated clinical manifestations affecting the cardiovascular, gastrointestinal, and central nervous systems. A multipronged approach has been recommended and has been associated with improved outcomes.
-
Pol. Arch. Med. Wewn. · Aug 2019
Long-term outcome of renal transplantation: a 10-year follow-up of 765 recipients.
Renal transplantation is a treatment of choice for patients with end‑stage renal disease. The main goal of transplant care is to achieve the best long‑term patient survival (PS) and graft survival (GS). ⋯ The effect of IS protocols on long‑term outcomes varies depending on patient subpopulations. Immunosuppressive therapy solves rejection‑related problems but does not address the increasing mortality of RTRs due to cardiovascular diseases, malignancies, or infections. Therefore, treatment recommendations should be individualized and posttransplant care, provided mainly by internists, should be carefully structured to improve long‑term outcomes of renal transplantation.
-
Pol. Arch. Med. Wewn. · Aug 2019
Comparative StudyEfficacy, tolerability, and safety of infliximab biosimilar in comparison to originator biologic and adalimumab in patients with Crohn disease.
An infliximab biosimilar has been shown to be equivalent to originator infliximab. However, data concerning the drug's efficacy and safety in patients with Crohn disease (CD) are still limited. ⋯ We showed the same efficacy and safety of the infliximab biosimilar in comparison to the originator drug and adalimumab in the Polish population, not only during induction and 1‑year therapy, but also during 12‑month follow‑up.